Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group is projected to experience a 4%-5% earnings boost in 2026, driven by a new partnership with FanDuel and expectations around prediction markets, with increased earnings per share (EPS) estimates of $11.14 and $11.38 for 2025 and 2026, respectively. Additionally, the company anticipates significant revenue growth opportunities from customer expansion, with the potential to generate over $300 million annually, further enhancing EPS as it capitalizes on new offerings. The positive financial outlook is strengthened by CME Group’s historical strategic mergers and partnerships, positioning the company for continued growth in the evolving trading landscape.

Bears say

CME Group faces significant regulatory risks that could lead to reduced trading volumes, as potential changes in margin requirements and limitations on high-frequency trading may adversely impact market activity. Additionally, the firm is vulnerable to fluctuations in industry fundamentals, including customer demand and pricing pressures, which could negatively affect projected revenues and earnings. Furthermore, credit risks associated with clearing operations heighten concerns about the company's financial stability, as defaults by clearing members could jeopardize working capital and overall financial health.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.